Summary Urokinase plasminogen activator (uPA) is a serine proteinase that has been suggested to play an important role in cancer invasion and metastasis. It binds to a specific membrane receptor denominated uPA receptor (uPAR Pancreatic cancer has one of the poorest prognoses of all gastrointestinal malignancies, being the fourth or fifth leading cause of cancer-related deaths in Western industrialized countries (Bomman et al, 1994) . Gudjonsson (1987) , in his classical review of 37 000 patients with pancreatic cancer, demonstrated an overall survival rate of 0.4% and a median survival time of 5 months after the diagnosis was established. Once pancreatic cancer is clinically evident, it progresses at a rapid rate, and metastasis has usually occurred at the time of diagnosis. Consequently, many patients are not resectable at presentation, and the overall resection rate is often less than 30% (Gudjonsson 1987; Bomman et al, 1994) . The mechanisms that regulate this aggressive growth behaviour in pancreatic cancer are not at all clear. Recently, it has been shown in pancreatic cancer that the concomitant overexpression of the epidermal growth factor (EGF) receptor and its ligands EGF-, TGF-alpha (Korc et al, 1992; Yamanaka et al, 1993a) and/or amphiregulin (Ebert et al, 1994a; Yokoyama et al., 1995a) is associated with shorter post-operative survival following tumour resection. In addition, enhanced expression of c-erbB-3 (Friess et al, 1995), TGF-fs and basic fibroblast growth
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Several studies indicate that, during cancer cell invasion and metastasis, proteolytic enzymes may participate in the degradation of extracellular matrix components (Fidler et al, 1978; Schmitt et al, 1992) . In the past, scientists have focused their attention on the pathways of plasminogen activation. Plasminogen is an inactive proenzyme which can be converted to plasmin by two types of plasminogen activators -uPA (urokinase plasminogen activator) and tPA (tissue plasminogen activator) (Dano et al, 1980) . It is tPA rather than uPA that is mainly involved in physiological activation of plasmin during intravascular thrombolysis (Collen, 1985) . On the other hand, uPA appears to play a pivotal role in pericellular proteolysis during cell migration and tissue remodelling (Blasi et al, 1987) .
uPA is initially released from various cells as an enzymatically inactive proenzyme (pro-uPA) which can be cleaved by serine proteinases, cysteine proteinases or thermolysin in its enzymatically active high molecular weight form or by thrombin and granulocyte elastase in enzymatically inactive high molecular weight uPA . Both uPA and pro-uPA bind with high affinity to a specific cell-surface receptor (uPA receptor). The uPA receptor (uPAR) is a cysteine-rich glycoprotein with an approximate molecular weight of 55-60 kDa. Receptor binding of uPA or pro-uPA strongly accelerates pro-uPA activation and increases the enzymatic activity of uPA itself (Ellis et al, 1989) . uPA converts the zymogen plasminogen to plasmin, an enzyme which degrades fibrin and a number of other components of the extracellular matrix, such as type IV collagen, fibronectin and laminin (Liotta et al, 1981; Dano et al, 1985) . Plasmin also activates latent collagenases to potentiate their lytic activity (Vassalli et al, 1991; Schmitt et al, 1992) . This activation at the cell surface may enable cells to exercise a focal and directional proteolysis of the extracellular matrix. Subsequently, plasmin formation facilitates the passage of migrating cells through tissue barriers (Estreicher et al, 1990) .
Recently, elevated levels of uPA have been reported in prostate (Achbarou et al, 1994) , lung (Pedersen et al, 1994) , ovarian (Schmalfeldt et al, 1995) , breast (Jankum et al, 1993; Bianchi at al, 1994) and gastrointestinal carcinomas (Kogha et al, 1989; Takai et al, 1991; Takeuchi et al, 1993) . However, only a few studies of colon (Pyke et al, 1991) and ovarian carcinomas (Schmalfeldt et al, 1995) and of breast (Del Vecchio et al, 1993; Duggan et al, 1995) adenocarcinomas have investigated the simultaneous expression of uPA and its receptor, showing that both factors appear to play a role in the process of tumour invasion and metastasis (Dano et al, 1992) . Because of the high metastatic and invasive potential of human pancreatic cancer cells, we have analysed in the present study the concomitant expression of uPA and its receptor in human pancreatic adenocarcinomas.
PATIENTS AND METHODS
Normal human pancreatic tissue samples were obtained from 30 previously healthy individuals (14 women, 16 men; median age 41 years, range 17-59 years) through an organ donor programme. Pancreatic cancer tissues were obtained from 12 female and 18 male patients undergoing surgery for pancreatic cancer at the University Hospital of Bern (Bern, Switzerland). The median age of the pancreatic cancer patients was 66.5 years, with a range of 32-79 years. Surgical procedure consisted of either a partial duodenopancreatectomy (28 patients) or a left resection of the pancreas (two patients). Seven patients had a tumour stage I, eight patients had a tumour stage II and 15 patients had a tumour stage III. Freshly removed pancreatic tissue samples were fixed in either Bouin solution or paraformaldehyde for 12-24 h and paraffin-embedded for histological analysis. Tissues destined for RNA extraction were frozen in liquid nitrogen immediately upon surgical removal and maintained at -80°C until use (Kobrin et al, 1993) . The study protocol was approved by the Ethics Committee of the University of Bern, Switzerland, and the University of California, Irvine, CA, USA.
Northern blot analysis
Total RNA was extracted by the guanidine isothiocyanate method, size-fractionated on denaturing 1.2% agarose/1.8 M formaldehyde gels and stained with ethidium bromide for verification of RNA integrity and loading equivalency (Chomczynski et al, 1987; Korc et al, 1992; Friess et al, 1993a,b; Yamanaka et al, 1993a) . The RNA was electrotransferred onto Nylon membranes (GeneScreen, DuPont, Boston, USA) and cross-linked by UV irradiation (Korc et al, 1992; Friess et al, 1993b; Yamanaka et al, 1993a) . The blots were then prehybridized, hybridized and washed under conditions appropriate for cDNA probes, as previously described (Korc et al, 1992; Friess et al, 1993b; Yamanaka et al, 1993a) . Blots were prehybridized overnight at 42°C in a buffer that contained 50% formamide, 1% sodium dodecyl sulphate (SDS), 0.75 M sodium chloride, 5 mm EDTA, 5x Denhardt's solution, 100 g ml-' salmon sperm DNA, 10% Dextran sulphate and 50 mM dihydrogen sodium orthophosphate (pH 7.4) . The hybridization was carried out at 42°C for 12 h with the 32P-labelled cDNA probe (lx 106 c.p.m. ml-'). Washing was started by rinsing the blots twice (50°C) in 2x standard saline citrate (SSC). Afterwards, the blots were washed three times at 55°C in 0.2x SSC and 2% SDS (Korc et al, 1992; Friess et al, 1993b; Yamanaka et al, 1993a) . Blots were then exposed at -80°C to Fuji radiographic film with intensifying screens, and the intensity of the radiographic bands was quantified by video densitometry (Biorad 620, USA), as previously reported (Korc et al, 1992; Friess et al, 1993b; Yamanaka et al, 1993a) .
Following membrane hybridization with the uPA and uPAR cDNA, all the membranes were rehybridized with the 7S cDNA probe to assess equivalent RNA loading (Korc et al, 1992; Friess et al, 1993b; Yamanaka et al, 1993a) .
cDNA probes were used for filter hybridizations. The uPA cDNA probe consisted of a 1.5-kb Pstl insert cloned from human SV40-transformed fibroblast (Blasi et al, 1987) , and the uPAR cDNA probe consisted of a 1.11-kb EcoRI/Xbal insert cloned from the human fibroblast GM637 cell line which was SV40-transformed (Roldan et al, 1990) . Both cDNAs were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The 7S cDNA probe consisted of a 0.19-kb BamHI fragment of the mouse 7S cytoplasmatic cDNA, which crosshybridizes with human 7S RNA (Ebert et al, 1994a) . cDNA probes were radiolabelled with [a-32P]dCTP (3000 Ci mmol-'; DuPont, Boston, USA) to a specific activity of 0.5-lx 109 d.p.m. gg-', using random hexanucleotide primers (BoehringerMannheim, Mannheim, Germany) (Korc et al, 1992; Friess et al, 1993b; Yamanaka et al, 1993a). uPA and uPAR immunohistochemistry Consecutive 3-to 5-,um paraffin-embedded tissue sections were subjected to immunostaining using the streptavidin-peroxidase technique (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA). Tissue sections were submerged for 15 min in Tris-buffered saline (TBS) (10mM Tris-HCl, 0.85% sodium chloride, pH 7.4) containing 0.1% (v/v) Triton X-100 and then were washed for 5 min in TBS, as previously reported (Friess et al, 1993b; Yamanaka et al, 1993a) . Endogenous peroxidase activity was blocked by incubating the slides in methanol and in methanol-0.6% hydrogen peroxide, followed by three washings in methanol and TBS containing 0.1% bovine serum albumin (BSA) (Friess et al, 1993b; Yamanaka et al, 1993a) . Following treatment with hyaluronidase (1 mg ml-' in 100 mm sodium acetate, 0.85% sodium chloride), the sections were incubated for 30 min at 37°C with 10% normal goat serum before overnight incubation at 4°C with the specific monoclonal antibodies (anti-uPA [Muk 11, Biopool, Umea, Sweden; American Diagnostica, Greenwich, CT, USA) diluted in 10% normal goat serum. Bound antibody was detected with a biotinylated goat antimouse IgG secondary antibody and a streptavidin-peroxidase complex (Kirkegaard and Perry Laboratories, USA). This was followed by incubation with diaminobenzidine tetrahydrochloride (0.05%) as the substrate and then counterstaining with Mayer's haematoxylin.
To ensure specificity of the immunostaining reactions, consecutive sections were incubated either in the absence of the primary antibody or with a non-immunized mouse IgG antibody. In both cases, no immunostaining was detected. Histopathological analysis of the immunohistochemical results was performed by two independent pathologists blinded to patient status, followed by resolution of any differences by joint review and consultation with a third observer.
The immunohistochemical results were semi-quantitatively analysed as previously reported (Saeki et al, 1992 
RESULTS

Immunohistochemical analysis
Immunohistochemical staining of uPA and uPAR and semiquantitative analysis were carried out in the same tumour specimens as those used for Northern blot analysis. In all cancer samples, there was close agreement between the results obtained by Northern blot analysis and immunohistochemistry (Table 1) .
uPA immunostaining
In the normal human pancreatic tissue samples, weak cytoplasmic uPA immunoreactivity was present ( Figure IA) . Approximately 20-30% of the small ductules and the same percentage of blood vessels exhibited faint uPA immunoreactivity in 25 of 30 (83%) normal pancreatic tissue samples. In the remaining five normal samples, no uPA immunostaining was detectable in these cell types. Only a few pancreatic acinar cells exhibited weak cytoplasmic uPA immunoreactivity in the normal pancreas ( Figure IA ). Figure 2B and Figure 3B British Journal of Cancer (1997) 
Northern blot analysis
In the normal pancreatic tissue samples obtained from previously healthy organ donors, low levels of uPA ( Figure 4A ) and uPAR ( Figure 4B ) mRNA were present. Both mRNA moieties were only weakly visible on the original autoradiographs in all normal samples. In contrast, 27 of 30 (90%) pancreatic cancer samples showed markedly increased levels of uPA mRNA ( Figure 4A ), and 22 of 30 (73.3%) samples showed markedly increased levels of uPAR mRNA ( Figure 4B and Table 1 ). Densitometric analysis of the Northern blots of all cancer samples indicated that uPA and uPAR were sixfold and fourfold increased, respectively, in the pancreatic cancer samples in comparison with normal controls (P<0.01).
Concomitant increased levels of uPA and uPAR mRNA expression were detected in 21 of the 30 (70%) pancreatic cancer samples (Table 1 , lower part). Only two pancreatic cancer samples (6.6%) exhibited mRNA levels for both uPA and uPAR which were similar to those of the normal controls. Six pancreatic cancer samples (20%) showed only overexpression of uPA, and in one cancer sample (3.3%) only uPAR mRNA overexpression was detectable.
Linear regression analysis of the Northern blot results revealed a significant correlation between the increase of uPA mRNA and its receptor in the cancer samples (r=0.62, P< 0.00 1).
To evaluate the clinical significance of the mRNA expression data in the pancreatic cancer samples, the Northern blot results
were correlated with the survival data after tumour resection (Table 1) . Patients whose tumours exhibited concomitant overexpression of uPA and uPAR had significantly shorter median postoperative survival periods (median 9 months; mean + s.d. 10.2±3.6 months) than patients whose tumours exhibited only overexpression of uPA or uPAR, as well as significantly shorter survival periods than patients whose tumours did not overexpress these factors (median 18 months; mean ± s.d. 20.3± 8.7 months). This difference was statistically significant when analysed by either the Wilcoxon test (P<0.003) or the log-rank test (P<0.006) ( Figure 5 ).
Multivariate analysis using the Cox regression -including uPA and uPAR mRNA expression, gender, age, tumour stage, type of operation, completeness of tumour resection and vascular infiltration -revealed that enhanced uPAR mRNA expression is a strong independent prognostic parameter for survival in these patients.
DISCUSSION
Cancer of the pancreas has a very poor prognosis, and the majority of patients die within a short time after the diagnosis has been established, regardless of the type of primary treatment they receive (resection, bypass or stenting). The reasons for the aggressive growth behaviour of pancreatic cancer cells are not well understood. Recent molecular studies have emphasized the importance of alterations in growth factors and their receptors in the pathogenesis of pancreatic cancer (Hull et al, 1990; Friess et al, 1996) . Furthermore, the concomitant overexpression of growth factor receptors and their ligands has been correlated with a worse prognosis in pancreatic cancer patients (Yamanaka et al, 1993a,b; Yokomana et al, 1995a ).
An important clinical characteristic of pancreatic cancer is early metastasis to lymph nodes and distant organs. However, the mechanisms that contribute to the ability of pancreatic cancer cells to invade normal tissue compartments and other organs and to leave the primary tumour lesion have not been studied in the past.
Proteinases are enzymes which are involved in proteolysis of the extracellular matrix, a mechanism which is important in tissue degradation and remodelling. In human malignancies, four subgroups of proteinases have been characterized which may contribute to tumour invasiveness and tumour spread: (a) metalloproteinases, (b) aspartyl proteinases, (c) cysteine proteinases and (d) serine proteinases. Recently, we have reported that metalloproteinase-2 and -9 are often overexpressed in human pancreatic cancers (Gress et al, 1995) . In addition, enhanced mRNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) and TIMP-2 is present in many pancreatic cancer samples (Gress et al, 1995) . These findings suggest that, in pancreatic cancer, upregulation of specific metalloproteinases might be important in tumour pathogenesis and might contribute to remodelling of the extracellular matrix.
In the present study, we have analysed uPA and uPAR in the pathogenesis of human pancreatic cancers. Northern blot analysis demonstrated a sixfold and a fourfold increase in uPA mRNA and uPAR mRNA expression, respectively, in the pancreatic cancer samples. In 70% of the pancreatic cancer samples, both factors were concomitantly overexpressed. Immunohistochemical analysis revealed the simultaneous presence of uPA and uPAR in most pancreatic cancer cells. In some cancer samples also, the stroma and degenerating acinar and ductal cells adjacent to the cancer lesions exhibited uPA and uPAR immunoreactivity. In particular, areas with invading cancer cells showed intense uPA and uPAR immunostaining in the tumour and in the adjacent stroma.
Our findings with regard to uPA and uPAR overexpression are in agreement with previous studies carried out in other solid tumours which indicate that both factors are also often concomitantly present at the protein level and that the presence of uPA and uPAR may contribute to tumour invasion and tumour spread and thereby to worse prognosis (Del Vecchio et al, 1993; Duggan et al, 1995) .
It is not surprising that uPA and uPAR immunoreactivity were present primarily in the cytoplasm of the cancer cells. The monoclonal antibodies against uPA that were used in our experiments specifically detect both free and receptor-bound uPA. In addition, the monoclonal uPAR antibody has been shown to recognize unbound and ligand-saturated receptor on the surface of haematopoietic cells, as well as soluble uPAR in the cytoplasm of normal leucocytes and tumour cells. These binding characteristics of the anti-uPAR antibody may explain why uPAR immunoreactivity was mainly detected in the cytoplasm of the cancer cells and not on the cell surface (Chucholowski et al, 1992) .
In four cancer samples, uPAR immunoreactivity was present in the cytoplasm and in the nuclei of the cancer cells. In contrast, we did not observe nuclear uPAR immunoreactivity in any of the normal tissue samples, nor was it present in the non-cancerous regions of the cancer samples. Nuclear uPAR immunostaining in the cancer cells was not associated with higher levels of uPA or uPAR gene expression. Furthermore, we could not find any association between nuclear uPAR immunostaining and clinical or histopathological characteristics of the patients. It is not obvious why uPAR is accumulated in the nuclei of the pancreatic cancer cells, but it might be possible that uPAR influences gene transcription, as it has been previously suggested for some growth factors and also for uPA (He et al, 1991) . Similar nuclear uPAR immunostaining has also been observed in some breast cancer samples, however the significance of this observation in breast cancer was also not obvious (Carriero et al, 1994) .
Concomitant uPA and uPAR immunoreactivity was present in many pancreatic cancer cells in our study. The presence of both the ligand and the receptor in the same cancer cells indicates that pancreatic cancer cells may have the ability to up-regulate plasminogen activation by uPA/uPAR production. Binding of uPA to its receptor enhances the enzymatic activity of uPA, which then accelerates the activation of plasminogen to plasmin. In addition to these mechanisms, uPAR-bound uPA is involved in the activation of growth factors. Besides hepatocyte growth factor (HGF) activation, which can be catalysed by uPA directly, activation of transforming growth factor betas (TGF-js) from their pro-forms, basic fibroblast growth factor (bFGF) mobilization and extracellular matrix degradation are mediated by plasmin and by uPAR-bound or free uPA (Fazioli et al, 1994) . These multifactorial effects of uPA/uPAR on growth factors and the increase in proteolysis might enhance the ability of pancreatic cancer cells to migrate, to invade normal tissue and to metastasize. These effects may be increased by the additional expression of uPA and uPAR in the surrounding stroma adjacent to the cancer cells.
In conclusion, we have shown that uPA and uPAR are overexpressed in human pancreatic cancer and that overexpression of both factors is associated with shorter post-operative survival after tumour resection. The presence of high levels of uPA and uPAR may be a new prognostic marker that would allow us to identify patients with poorer prognosis who might benefit from more aggressive surgical and adjuvant treatment (Ossowski et al, 1991) .
